KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Cash & Current Investments (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Cash & Current Investments for 7 consecutive years, with $637.5 million as the latest value for Q4 2025.

  • Quarterly Cash & Current Investments fell 35.43% to $637.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $637.5 million through Dec 2025, down 35.43% year-over-year, with the annual reading at $637.5 million for FY2025, 35.43% down from the prior year.
  • Cash & Current Investments hit $637.5 million in Q4 2025 for Royalty Pharma, down from $955.0 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $2.5 billion in Q2 2022 to a low of $495.3 million in Q4 2023.
  • Historically, Cash & Current Investments has averaged $1.3 billion across 5 years, with a median of $1.2 billion in 2021.
  • Biggest five-year swings in Cash & Current Investments: skyrocketed 976.21% in 2021 and later plummeted 71.07% in 2023.
  • Year by year, Cash & Current Investments stood at $1.6 billion in 2021, then increased by 6.53% to $1.7 billion in 2022, then tumbled by 71.07% to $495.3 million in 2023, then surged by 99.31% to $987.2 million in 2024, then plummeted by 35.43% to $637.5 million in 2025.
  • Business Quant data shows Cash & Current Investments for RPRX at $637.5 million in Q4 2025, $955.0 million in Q3 2025, and $645.1 million in Q2 2025.